{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T03:20:43Z","timestamp":1770348043091,"version":"3.49.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"name":"EORTC Cancer Research Fund"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.ejca.2015.10.012","type":"journal-article","created":{"date-parts":[[2015,12,24]],"date-time":"2015-12-24T23:06:19Z","timestamp":1450998379000},"page":"144-154","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["A European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT00066378)"],"prefix":"10.1016","volume":"53","clinical-trial-number":[{"clinical-trial-number":"nct00066378","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Konstantinos","family":"Tryfonidis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gul","family":"Basaran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Bogaerts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Debled","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc","family":"Dirix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Christophe","family":"Thery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivianne C.G.","family":"Tjan-Heijnen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle","family":"Van den Weyngaert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanja","family":"Cufer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martine","family":"Piccart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Cameron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.ejca.2015.10.012_bib1","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1200\/JCO.2000.18.22.3748","article-title":"Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study","volume":"18","author":"Bonneterre","year":"2000","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.ejca.2015.10.012_bib2","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1200\/JCO.2000.18.22.3758","article-title":"Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group","volume":"18","author":"Nabholtz","year":"2000","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2015.10.012_bib3","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1002\/1097-0142(20011101)92:9<2247::AID-CNCR1570>3.0.CO;2-Y","article-title":"Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma","volume":"92","author":"Bonneterre","year":"2001","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2015.10.012_bib4","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1677\/erc.0.0060373","article-title":"Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer","volume":"6","author":"Nicholson","year":"1999","journal-title":"Endocr Relat Cancer"},{"issue":"9","key":"10.1016\/j.ejca.2015.10.012_bib5","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/annonc\/mdg365","article-title":"Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer","volume":"14","author":"Atalay","year":"2003","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2015.10.012_bib6","doi-asserted-by":"crossref","first-page":"5105","DOI":"10.1210\/en.2003-0705","article-title":"The antiepidermal growth factor receptor agent gefitinib (ZD1839\/Iressa) improves antihormone response and prevents development of resistance in breast cancer in\u00a0vitro","volume":"144","author":"Gee","year":"2003","journal-title":"Endocrinology"},{"issue":"2","key":"10.1016\/j.ejca.2015.10.012_bib7","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/jcp.20588","article-title":"The MEK\/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib","volume":"207","author":"Normanno","year":"2006","journal-title":"J Cell Physiol"},{"issue":"16","key":"10.1016\/j.ejca.2015.10.012_bib8","doi-asserted-by":"crossref","first-page":"8266","DOI":"10.1158\/0008-5472.CAN-05-4045","article-title":"Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2\/neu-positive breast cancer","volume":"66","author":"Massarweh","year":"2006","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.ejca.2015.10.012_bib9","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1470-2045(05)70176-5","article-title":"Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial","volume":"6","author":"Polychronis","year":"2005","journal-title":"Lancet Oncol"},{"issue":"25","key":"10.1016\/j.ejca.2015.10.012_bib10","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1200\/JCO.2006.09.6578","article-title":"A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer","volume":"25","author":"Smith","year":"2007","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2015.10.012_bib11","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2015.10.012_bib12","series-title":"Guideline on the evaluation of anticancer medicinal products in man (CPMP\/EWP\/205\/95\/Rev.3)","author":"European Medicines Agency [homepage on the Internet]","year":"2006"},{"issue":"7","key":"10.1016\/j.ejca.2015.10.012_bib13","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/sim.704","article-title":"A flexible design for multiple armed screening trials","volume":"20","author":"Sargent","year":"2001","journal-title":"Stat Med"},{"issue":"3","key":"10.1016\/j.ejca.2015.10.012_bib14","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.2517-6161.1976.tb01597.x","article-title":"The empirical distribution function with arbitarily grouped, censored and truncated data","volume":"38","author":"Bruce","year":"1976","journal-title":"J R Stat Soc Ser B Methodol"},{"issue":"6","key":"10.1016\/j.ejca.2015.10.012_bib15","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1158\/1078-0432.CCR-09-2282","article-title":"Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer","volume":"16","author":"Cristofanilli","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.ejca.2015.10.012_bib16","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1158\/1078-0432.CCR-10-1869","article-title":"Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study","volume":"17","author":"Osborne","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"Suppl. 1","key":"10.1016\/j.ejca.2015.10.012_bib17","first-page":"A-1117","article-title":"A phase II and biologic correlative study investigating anastrazole (A) in combination with gefitinib (G) in post- menopausal patients with estrogen receptor positive (ER) metastatic breast carcinoma (MBC) who have previously failed hormonal therapy","volume":"94","author":"Mita","year":"2005","journal-title":"Breast Cancer Res Treat"},{"issue":"Suppl. 1","key":"10.1016\/j.ejca.2015.10.012_bib18","first-page":"S33","article-title":"Open label, phase II, multicenter trial of ZD 1839 (Iressa) in patients with advanced cancer","volume":"76","author":"Albain","year":"2002","journal-title":"Breast Cancer Res Treat"},{"issue":"11","key":"10.1016\/j.ejca.2015.10.012_bib19","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1093\/annonc\/mdp202","article-title":"Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer","volume":"20","author":"Green","year":"2009","journal-title":"Ann Oncol"},{"issue":"23","key":"10.1016\/j.ejca.2015.10.012_bib20","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1200\/JCO.2005.08.326","article-title":"Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer","volume":"23","author":"Baselga","year":"2005","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2015.10.012_bib21","article-title":"Gefitinib is active in acquired tamoxifen (TAM)-resistant estrogen receptor (ER)-positive and (ER)-negative breast cancer: results from phase II study","volume":"22","author":"Robertson","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2015.10.012_bib22","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s10549-012-1997-5","article-title":"A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer","volume":"133","author":"Carlson","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"10.1016\/j.ejca.2015.10.012_bib23","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1158\/1535-7163.MCT-08-0805","article-title":"Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer","volume":"8","author":"McGovern","year":"2009","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"10.1016\/j.ejca.2015.10.012_bib24","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2015.10.012_bib25","article-title":"Everolimus for postmenopausal women with advanced breast cancer: updated results of the BOLERO-2 phase III trial","volume":"30","author":"Piccart","year":"2012","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2015.10.012_bib26","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1505270","article-title":"Palbociclib in hormone-receptor-positive advanced breast cancer","volume":"373","author":"Turner","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejca.2015.10.012_bib27","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(14)71159-3","article-title":"The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): a randomised phase 2 study","volume":"16","author":"Finn","year":"2015","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2015.10.012_bib28","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nrclinonc.2013.29","article-title":"Emerging targeted agents in metastatic breast cancer","volume":"10","author":"Zardavas","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2015.10.012_bib29","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/CCO.0b013e328358a2b5","article-title":"Phosphatidylinositol 3-kinase\/AKT\/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+\/HER2-) breast cancers?","volume":"24","author":"Zardavas","year":"2012","journal-title":"Curr Opin Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2015.10.012_bib30","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nrclinonc.2015.73","article-title":"Clinical management of breast cancer heterogeneity","volume":"12","author":"Zardavas","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2015.10.012_bib31","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1002\/ijc.29612","article-title":"Short report: monitoring ESR1 mutations by circulating tumor DNA in aromatase inhibitor resistant metastatic breast cancer","volume":"137","author":"Sefrioui","year":"2015","journal-title":"Int J Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804915009260?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804915009260?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T11:13:23Z","timestamp":1718277203000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804915009260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":31,"alternative-id":["S0959804915009260"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2015.10.012","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT00066378)","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2015.10.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}